NO20052796D0 - Indolylpyrazinone derivatives useful for the treatment of hyperproliferative disorders and disorders associated with angiogenesis - Google Patents
Indolylpyrazinone derivatives useful for the treatment of hyperproliferative disorders and disorders associated with angiogenesisInfo
- Publication number
- NO20052796D0 NO20052796D0 NO20052796A NO20052796A NO20052796D0 NO 20052796 D0 NO20052796 D0 NO 20052796D0 NO 20052796 A NO20052796 A NO 20052796A NO 20052796 A NO20052796 A NO 20052796A NO 20052796 D0 NO20052796 D0 NO 20052796D0
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- indolylpyrazinone
- angiogenesis
- treatment
- derivatives useful
- Prior art date
Links
- YVFNMQLTCRSZOJ-UHFFFAOYSA-N 3-(1h-indol-2-yl)-1h-pyrazin-2-one Chemical class O=C1NC=CN=C1C1=CC2=CC=CC=C2N1 YVFNMQLTCRSZOJ-UHFFFAOYSA-N 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42549002P | 2002-11-12 | 2002-11-12 | |
| US46091503P | 2003-04-07 | 2003-04-07 | |
| US48420203P | 2003-06-30 | 2003-06-30 | |
| PCT/US2003/036003 WO2004043950A1 (en) | 2002-11-12 | 2003-11-10 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052796L NO20052796L (en) | 2005-06-09 |
| NO20052796D0 true NO20052796D0 (en) | 2005-06-09 |
Family
ID=32314888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052796A NO20052796D0 (en) | 2002-11-12 | 2005-06-09 | Indolylpyrazinone derivatives useful for the treatment of hyperproliferative disorders and disorders associated with angiogenesis |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1565455A1 (en) |
| JP (1) | JP2006509840A (en) |
| KR (1) | KR20050072824A (en) |
| AR (1) | AR043059A1 (en) |
| AU (1) | AU2003290744A1 (en) |
| BR (1) | BR0316169A (en) |
| CA (1) | CA2505819A1 (en) |
| EC (1) | ECSP055851A (en) |
| HR (1) | HRP20050496A2 (en) |
| MA (1) | MA27557A1 (en) |
| MX (1) | MXPA05004779A (en) |
| NO (1) | NO20052796D0 (en) |
| PE (1) | PE20040832A1 (en) |
| PL (1) | PL376867A1 (en) |
| TW (1) | TW200418834A (en) |
| UY (1) | UY28074A1 (en) |
| WO (1) | WO2004043950A1 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| NZ546990A (en) | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| EP1687313A1 (en) * | 2003-11-21 | 2006-08-09 | Bayer Pharmaceuticals Corporation | Indolyl-thien 3,4-b]pyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| AU2005259189B2 (en) | 2004-06-30 | 2011-04-21 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as PARP inhibitors |
| WO2006003148A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
| CN1976906B (en) | 2004-06-30 | 2010-09-01 | 詹森药业有限公司 | Substituted 2-alkylquinazolinone derivatives useful as PARP inhibitors |
| BRPI0517734A (en) | 2004-11-17 | 2008-10-21 | Korea Res Inst Chem Tech | 1 - [(6,7-substituted alkoxyquinoxalinyl) aminocarbonyl] -4- (hetero) arylpiperazine derivatives |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| KR101533268B1 (en) | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | Apoptosis promoters |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| JP5545955B2 (en) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Quinolinone derivatives as PARP and TANK inhibitors |
| JP5492183B2 (en) | 2008-03-27 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Tetrahydrophenanthridinone and tetrahydrocyclopentaquinolinone as PARP and tubulin polymerization inhibitors |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| US20100113514A1 (en) | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| CA2741537A1 (en) * | 2008-11-07 | 2010-05-14 | Wyeth Llc | Quinoxaline-based lxr modulators |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| HUE053653T2 (en) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | Combinations of FGFR inhibitor and IGF1R inhibitor |
| ES3014202T3 (en) | 2014-03-26 | 2025-04-21 | Astex Therapeutics Ltd | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| WO2015161142A1 (en) | 2014-04-18 | 2015-10-22 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
| CN107438598A (en) | 2015-01-20 | 2017-12-05 | 米伦纽姆医药公司 | Quinazoline and quinoline compounds and uses thereof |
| JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| RU2747644C2 (en) | 2015-09-23 | 2021-05-11 | Янссен Фармацевтика Нв | Bigeteroaryl-substituted 1,4-benzodiazepines and ways of their use for cancer treatment |
| HRP20201157T1 (en) | 2015-09-23 | 2020-11-13 | Janssen Pharmaceutica N.V. | Tricyclic heterocycles for the treatment of cancer |
| KR20240099221A (en) * | 2021-09-29 | 2024-06-28 | 리페어 세라퓨틱스 인크. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and their use for inhibiting human polymerase theta |
| EP4594316A1 (en) * | 2022-09-29 | 2025-08-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW472045B (en) * | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
-
2003
- 2003-11-05 AR ARP030104059A patent/AR043059A1/en unknown
- 2003-11-10 MX MXPA05004779A patent/MXPA05004779A/en not_active Application Discontinuation
- 2003-11-10 CA CA002505819A patent/CA2505819A1/en not_active Abandoned
- 2003-11-10 AU AU2003290744A patent/AU2003290744A1/en not_active Abandoned
- 2003-11-10 PL PL376867A patent/PL376867A1/en unknown
- 2003-11-10 BR BR0316169-2A patent/BR0316169A/en not_active Application Discontinuation
- 2003-11-10 WO PCT/US2003/036003 patent/WO2004043950A1/en not_active Ceased
- 2003-11-10 JP JP2005507146A patent/JP2006509840A/en active Pending
- 2003-11-10 KR KR1020057008396A patent/KR20050072824A/en not_active Withdrawn
- 2003-11-10 EP EP03783328A patent/EP1565455A1/en not_active Withdrawn
- 2003-11-10 HR HR20050496A patent/HRP20050496A2/en not_active Application Discontinuation
- 2003-11-11 UY UY28074A patent/UY28074A1/en not_active Application Discontinuation
- 2003-11-11 TW TW092131443A patent/TW200418834A/en unknown
- 2003-11-11 PE PE2003001136A patent/PE20040832A1/en not_active Application Discontinuation
-
2005
- 2005-06-09 NO NO20052796A patent/NO20052796D0/en not_active Application Discontinuation
- 2005-06-09 MA MA28322A patent/MA27557A1/en unknown
- 2005-06-10 EC EC2005005851A patent/ECSP055851A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200418834A (en) | 2004-10-01 |
| NO20052796L (en) | 2005-06-09 |
| EP1565455A1 (en) | 2005-08-24 |
| HRP20050496A2 (en) | 2006-06-30 |
| WO2004043950A1 (en) | 2004-05-27 |
| PE20040832A1 (en) | 2005-01-27 |
| UY28074A1 (en) | 2004-05-31 |
| AR043059A1 (en) | 2005-07-13 |
| BR0316169A (en) | 2005-09-27 |
| CA2505819A1 (en) | 2004-05-27 |
| AU2003290744A1 (en) | 2004-06-03 |
| MA27557A1 (en) | 2005-10-03 |
| MXPA05004779A (en) | 2005-07-22 |
| PL376867A1 (en) | 2006-01-09 |
| JP2006509840A (en) | 2006-03-23 |
| KR20050072824A (en) | 2005-07-12 |
| ECSP055851A (en) | 2005-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052796D0 (en) | Indolylpyrazinone derivatives useful for the treatment of hyperproliferative disorders and disorders associated with angiogenesis | |
| NO20051493L (en) | Imidazole pyridines and processes for the preparation and use of the same | |
| NO20055152D0 (en) | Carbon styrene derivatives and humor stabilizers for the treatment of humor disorders | |
| HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| NO20031626D0 (en) | Pyridone derivatives for the treatment of atherosclerosis | |
| NO20013380L (en) | 2-aminobenzoxazinone derivatives for the treatment of obesity | |
| NO20013381D0 (en) | 2-oxybenzoxazinone derivatives for the treatment of obesity | |
| GB0312832D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| NO20041216L (en) | Imidazole-4-carboxamide derivatives, preparation and use thereof for the treatment of obesity | |
| SI1599467T1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
| AU2003284808A8 (en) | The derivatives of pyridone and the use of them | |
| NO20032801D0 (en) | Thiazole derivatives for the treatment of PPAR related disorders | |
| NO20043237L (en) | Dihydrobenzodiazepine-2-derivatives for the treatment of neurological disorders | |
| NO20055832D0 (en) | Preparation and use of arylalkyl acid derivatives for the treatment of obesity | |
| IS2907B (en) | Benzo [d] asepin derivatives for the treatment of neurological disorders | |
| DK1448198T3 (en) | Nicotine or isonicotine benzothiazole derivatives | |
| DE60319951D1 (en) | AMINOCYCLIC SUBSTITUTED PYRROLOPYRIMIDIN DERIVATIVES AND PYRROLOPYRIDINE DERIVATIVES | |
| NO20026263L (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| NO20032636D0 (en) | 3-indoline derivatives useful in the treatment of psychiatric and neurological disorders | |
| NO20043986L (en) | Tasty oral suspension and method of preparing the suspension. | |
| NO20051503D0 (en) | Pyrazolopyridines and processes for the preparation and use of the same. | |
| SI1231920T1 (en) | Use of epinastin for the treatment of allergic rhinitis/conjunctivitis | |
| NO20024775D0 (en) | Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
| NO20050569D0 (en) | Procedure for the treatment of severe heart failure and drug for this | |
| PL377164A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |